BEAT Bio Therapeutics

Launched: 

2012

Sector: 

BEAT BioTherapeutics is developing BB-R12, a novel biological therapy with the potential to revolutionize the treatment of heart failure. BEATBio holds worldwide rights to this technology and its UW founders are recognized experts in cardiovascular biology, muscle physiology and bioengineering. 

BEAT Bio Therapeutics Team
PatLorro temporerum, cusamendit, ut vendestem quam, omnihit alibus. Uptasitatur? Udae vid eatis il ipie- nis ratecum facil is serumen destrum dero expliqui offic t
Sample Image 2
PatLorro temporerum, cusamendit, ut vendestem quam, omnihit alibus. Uptasitatur? Udae vid eatis il ipie- nis ratecum facil is serumen destrum dero expliqui offic tOrrum endaesc idundit eum faccum harum quas acearum volupturit dit aperia sequis est ut hariam, cust, aut fugiat. Orrum endaesc idundit eum faccum harum quas acearum volupturit dit aperia sequis est ut hariam, cust, aut fugiat.

Team: 

Michael Kranda, CEO
Gregory Mahairas, President & Chief Scientific Officer
Sam Teichman, Chief Medical Officer